Physician profile
Cori Randall
NPI 1083182174
$1,181.08
in general payments reported to CMS, 2019-2025
15 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $204 · 2023: $302 · 2024: $297 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $234.14 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.80 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $177.26 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $141.97 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.67 | 2021-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $71.40 | 2022-2023 | |
| Exact Sciences Corporation | $47.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $45.21 | 2021-2022 | |
| Amgen INC. | $36.24 | 2023 | Evenity, Prolia |
| Ultragenyx Pharmaceutical INC. | $32.83 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $25.52 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $20.72 | 2021 | |
| Abbvie INC. | $14.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.57 | 2022 | |
| Glaxosmithkline, LLC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cori Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.